K Number
K090095
Device Name
LUNGPOINT VIRTUAL BRONCHOSCOPIC NAVIGATION VBN SYSTEM
Date Cleared
2009-03-13

(57 days)

Product Code
Regulation Number
892.2050
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
Indicated for displaying images of the tracheobronchial tree to aid the physician in guiding endoscopic tools or catheters in the pulmonary tract and to enable marker placement within soft lung tissue. It does not make a diagnosis and is not an endoscopic tool. Not for pediatric use.
Device Description
This premarket notification covers Broncus' LungPoint VBN System. The VBN System is a software only device, providing a navigation system to help the bronchoscopist plan and proceed to a predefined target site in the tracheobronchial tree. Specifically, the VBN system provides global quidance to targets preselected by the bronchoscopist in peripheral airways. In doing so, the VBN can provide local guidance to lymph nodes to enable tissue sampling. It can also facilitate the return to an exact location in the lungs that had previously been treated for assessment of or continued therapy. The VBN software is installed on an off-the-shelf PC computer system, and is intended to be used with commercially-available flexible bronchoscopes with HRCT scans that are saved in DICOM format.
More Information

Reference Device(s) K/DEN number: Not Found

No
The document does not mention AI, ML, or related terms, and the description of the technology focuses on navigation based on pre-selected targets and image processing, not learning algorithms.

No.
The device is indicated for displaying images and guiding endoscopic tools, not for directly treating or curing a medical condition.

No
The "Intended Use / Indications for Use" states, "It does not make a diagnosis."

Yes

The device description explicitly states, "The VBN System is a software only device". While it utilizes an off-the-shelf PC and commercially-available bronchoscopes, the core medical device functionality described is solely within the software for navigation and guidance.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. They are used to provide information for diagnosis, monitoring, or screening.
  • Device Function: The description clearly states that this device is a software-only navigation system that uses HRCT scans to guide a physician during bronchoscopic procedures. It displays images and aids in guiding tools within the pulmonary tract.
  • Lack of Sample Analysis: The device does not analyze any biological samples taken from the patient. Its input is image data (HRCT scans).
  • Intended Use: The intended use is to aid in guiding endoscopic tools and marker placement, not to perform diagnostic tests on patient samples. It explicitly states it "does not make a diagnosis."

Therefore, this device falls under the category of a medical device used for image-guided procedures, not an in vitro diagnostic device.

N/A

Intended Use / Indications for Use

Indicated for displaying images of the tracheobronchial tree to aid the physician in guiding endoscopic tools or catheters in the pulmonary tract and to enable marker placement within soft lung tissue. It does not make a diagnosis and is not an endoscopic tool. Not for pediatric use.

Product codes

LLZ

Device Description

This premarket notification covers Broncus' LungPoint VBN System. The VBN System is a software only device, providing a navigation system to help the bronchoscopist plan and proceed to a predefined target site in the tracheobronchial tree. Specifically, the VBN system provides global quidance to targets preselected by the bronchoscopist in peripheral airways. In doing so, the VBN can provide local guidance to lymph nodes to enable tissue sampling. It can also facilitate the return to an exact location in the lungs that had previously been treated for assessment of or continued therapy.

The VBN software is installed on an off-the-shelf PC computer system, and is intended to be used with commercially-available flexible bronchoscopes with HRCT scans that are saved in DICOM format.

Mentions image processing

Yes

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

HRCT scans

Anatomical Site

tracheobronchial tree, pulmonary tract, soft lung tissue

Indicated Patient Age Range

Not for pediatric use.

Intended User / Care Setting

bronchoscopist / Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

An animal study was conducted to evaluate the accuracy of the VBN system during bronchoscopic follow-up procedures in a canine model. Accuracy was assessed by determining the mean and standard deviation of the distance error between the virtual targets defined in the virtual rendering and the actual target in the real bronchoscope video.

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

An animal study was conducted to evaluate the accuracy of the VBN system during bronchoscopic follow-up procedures in a canine model. The results of the study indicate that the distance error of the VBN system is 2.17 +/- 0.84 mm.

The results of the animal study corroborated the outcome of an earlier phantom study performed by Merritt et al, which showed that the mean and standard deviation of the distance error of the VBN system is 2.2 +/- 2.3 mm.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Distance error of the VBN system is 2.17 +/- 0.84 mm (animal study).
Distance error of the VBN system is 2.2 +/- 2.3 mm (phantom study).

Predicate Device(s)

K080271, K042438

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 892.2050 Medical image management and processing system.

(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).

0

K090055

510(k) Summary

1. Date of Summary

December 11, 2008

510(k) Applicant 2.

Broncus Technologies, Inc. 1400 N. Shoreline Blvd., Bldg. A, Suite 8 Mountain View, California 94043 Phone: (650) 428-1600 FAX: (650) 428-1542

Contact Person:Mahtab Fatemi
Phone:(650) 428-1600, x320
Fax:(650) 428-1542
e-mail:mfatemi@broncus.com

3. Device Overview

Trade Name:LungPoint™ Virtual Bronchoscopic Navigation (VBN) System
Common Name:Picture Archiving and Communications Systems
Classification Name:System, Image Processing, Radiological
21 CFR 892.2050
Product Code LLZ

4. Predicate Device

The predicate device identified for the LungPoint VBN is as follows:

Trade Name510(k) Submitter510(k) Number
superDimension®/Bronchus
inReach™ SystemsuperDimension, LtdK080271, cleared on
March 31, 2008
superDimension/BronchussuperDimension, LtdK042438, cleared on
November 8, 2004

5. Device Description

This premarket notification covers Broncus' LungPoint VBN System. The VBN System is a software only device, providing a navigation system to help the bronchoscopist plan

MAR ] 3 2009

1

Image /page/1/Picture/0 description: The image is a black and white abstract shape. The shape is mostly black, with a small amount of white along the bottom edge. The shape is irregular and does not resemble any particular object. The image is simple and minimalist.

and proceed to a predefined target site in the tracheobronchial tree. Specifically, the VBN system provides global quidance to targets preselected by the bronchoscopist in peripheral airways. In doing so, the VBN can provide local guidance to lymph nodes to enable tissue sampling. It can also facilitate the return to an exact location in the lungs that had previously been treated for assessment of or continued therapy.

The VBN software is installed on an off-the-shelf PC computer system, and is intended to be used with commercially-available flexible bronchoscopes with HRCT scans that are saved in DICOM format.

6. Intended Use

Indicated for displaying images of the tracheobronchial tree to aid the physician in guiding endoscopic tools or catheters in the pulmonary tract and to enable marker placement within soft lung tissue. It does not make a diagnosis and is not an endoscopic tool. Not for pediatric use.

Comparison to Predicate Device 7.

The LungPoint VBN software is substantially equivalent to the predicate. The VBN software has the same intended use and similar technological characteristics as the predicate. The difference in technological characteristics, specifically the navigation method of the VBN software, does not raise any new questions of safety or effectiveness.

8. Performance Data

An animal study was conducted to evaluate the accuracy of the VBN system during bronchoscopic follow-up procedures in a canine model. Accuracy was assessed by determining the mean and standard deviation of the distance error between the virtual targets defined in the virtual rendering and the actual target in the real bronchoscope video. The results of the study indicate that the distance error of the VBN system is 2.17 +/- 0.84 mm.

The results of the animal study corroborated the outcome of an earlier phantom study performed by Merritt et al, which showed that the mean and standard deviation of the distance error of the VBN system is 2.2 +/- 2.3 mm.

Safety and Effectiveness 9.

The VBN labeling contains instructions for use and any necessary cautions and warnings, to provide for safe and effective use of the software. Risk management is ensured via a hazard analysis and FMEA, which are used to identify potential hazards. These potential hazards are controlled via software development, verification testing and validation testing.

2

Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged in a circular fashion around the symbol. The logo is black and white.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

MAR 1 3 2009

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Broncus Technologies, Inc. % Mr. Mark Job Responsible Third Party Official Regulatory Technology Services, LLC 1394 25th Street NW BUFFALO MN 55313

Re: K090095

Trade/Device Name: LungPoint™ Virtual Bronchoscopic Navigation (VBN) Software Regulation Number: 21 CFR 892.2050

· Regulation Name: Picture archiving and communications systems

Regulatory Class: II

Product Code: LLZ

Dated: February 19, 2009

Received: February 20, 2009

Dear Mr. Job:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If vour device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

3

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding os substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter.

21 CFR 876.xxx(Gastroenterology/Renal/Urology)(240) 276-0115
21 CFR 884.xxx(Obstetrics/Gynecology)(240) 276-0115
21 CFR 892.xxx(Radiology)(240) 276-0120
Other(240) 276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufactures, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry.suppot/index.html.

Sincerely yours,

Janine M. Norris

Janine M. Morris Acting Director, Division of Reproductive. Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

4

Indications for Use

510(k) Number (if known):

K 90095

Device Name:

Indications for Use:

LungPoint™ Virtual Bronchoscopic Navigation (VBN) Software

Indicated for displaying images of the tracheobronchial tree to aid the physician in guiding endoscopic tonlond catheters in the pulmonary tract and to enable marker placement within soft lung tissue. It does not make a diagnosis and is not an endoscopic tool. Not for pediatric use.

Prescription Use
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-CounterUse (21 CFR 801 Subpart C)

(Please do Not WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off) Division of Reproductive, Abdominal and Radiological Devices 510(k) Number

Page of

Broncus Technologies, Inc.

CONFIDENTIAL

17